<?xml version="1.0" encoding="UTF-8"?>
<p>Meanwhile, emerging candidates for ‘universal’ vaccines focus on the exclusive expression of cross-protective immunogens, whether T-cell targets [
 <xref rid="pcbi.1005204.ref023" ref-type="bibr">23</xref>, 
 <xref rid="pcbi.1005204.ref024" ref-type="bibr">24</xref>] or the conserved HA stem [
 <xref rid="pcbi.1005204.ref017" ref-type="bibr">17</xref>, 
 <xref rid="pcbi.1005204.ref019" ref-type="bibr">19</xref>, 
 <xref rid="pcbi.1005204.ref035" ref-type="bibr">35</xref>]. Such vaccines have shown protection against heterosubtypic challenge in animal models [
 <xref rid="pcbi.1005204.ref019" ref-type="bibr">19</xref>, 
 <xref rid="pcbi.1005204.ref024" ref-type="bibr">24</xref>, 
 <xref rid="pcbi.1005204.ref035" ref-type="bibr">35</xref>], as well as in human challenge studies [
 <xref rid="pcbi.1005204.ref036" ref-type="bibr">36</xref>]. A limitation amongst T-cell vaccines in particular is that—unlike immunity to HA or NA—they do not block infection, but rather control the severity of disease [
 <xref rid="pcbi.1005204.ref037" ref-type="bibr">37</xref>]. Nonetheless, in doing so, they substantially reduce the amount and duration of viral shedding, thus reducing opportunities for transmission [
 <xref rid="pcbi.1005204.ref024" ref-type="bibr">24</xref>, 
 <xref rid="pcbi.1005204.ref036" ref-type="bibr">36</xref>].
</p>
